XenoPort Urges Stockholders to Vote "FOR ALL" XenoPort Director Nominees on the WHITE Proxy Card Business Wire SANTA CLARA, Calif. -- June 6, 2014 XenoPort, Inc.(Nasdaq:XNPT) today reminded stockholders to vote at the Company’s upcoming Annual Meeting of Stockholders on June 11, 2014. Time is short and stockholders are encouraged to vote the WHITE proxy card today. XenoPort urges stockholders not to return any proxy card sent to them by Clinton Relational Opportunity Master Fund, L.P.and its affiliates (Clinton). Even if stockholders have already voted using the gold proxy card, they have the right to change their vote simply by executing and submitting the WHITE proxy card in support of XenoPort’s director nominees. Only the last-dated proxy card will count. Stockholders can vote by telephone or Internet according to the instructions on the WHITE proxy card.Voting by telephone or Internet is the best way to ensure that votes will be counted. Two independent proxy advisory firms, Institutional Shareholder Services (ISS) and Egan-Jones Proxy Services (Egan-Jones), have recommended that XenoPort stockholders vote on the WHITE proxy card “FOR ALL” of XenoPort’s director nominees: Ronald W. Barrett, Ph.D.,Jeryl L. HillemanandWendell Wierenga, Ph.D. XenoPort also urges stockholders to vote "FOR" the approval of theXenoPort, Inc.2014 Equity Incentive Plan, vote "FOR" the approval, on an advisory basis, of the compensation of XenoPort's named executive officers, and vote "FOR" the ratification of the selection by the audit committee of the Board of Directors ofErnst & Young LLPas XenoPort's independent registered public accounting firm for the fiscal year endingDecember 31, 2014. In addition, the XenoPort Board urges stockholders to vote "FOR" Proposals 9 through 14 and "AGAINST" Clinton Proposals 5 through 8. If you have any questions, require assistance with voting your WHITE proxy card or need additional copies of the proxy materials, please contact: MACKENZIE PARTNERS, INC. 105 Madison Avenue New York, NY 10016 firstname.lastname@example.org (212) 929-5500 (Call Collect) Or TOLL-FREE (800) 322-2885 Important Additional Information and Where to Find It XenoPort, Inc., its directors and certain of its executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with XenoPort's 2014 Annual Meeting of Stockholders.XenoPorthas filed with theSECand provided to its stockholders a definitive proxy statement and aWHITEproxy card in connection with such solicitation. XENOPORT STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS AND SUPPLEMENTS) AND THE ACCOMPANYINGWHITEPROXY CARD, AND ANY OTHER RELEVANT DOCUMENTS WHEN THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Information regarding the names of XenoPort's directors and executive officers and their respective interests inXenoPortby security holdings or otherwise is set forth in XenoPort's definitive proxy statement for the 2014 Annual Meeting of Stockholders, filed with theSEConApril 22, 2014, including Appendix B thereto. The definitive proxy statement (and amendments or supplements thereto) and the accompanyingWHITEproxy card, and any other relevant documents and other material filed byXenoPortwith theSEC, are or will be available for no charge at the SEC's website atwww.sec.govand at XenoPort's investor relations website athttp://investor.xenoport.com/index.cfm. Copies may also be obtained free of charge by contacting XenoPortInvestor Relations by mail at3410 Central Expressway,Santa Clara, California95051 or by telephone at (408) 616-7200. AboutXenoPort XenoPort, Inc.is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders.XenoPortis currently commercializing HORIZANT^® (gabapentin enacarbil) Extended-Release Tablets inthe United Statesand developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for psoriasis and/or relapsing forms of multiple sclerosis. REGNITE^® (gabapentin enacarbil) Extended-Release Tablets is being marketed inJapanby Astellas Pharma Inc. XenoPort'spipeline of product candidates also includes a potential treatment for patients with Parkinson's disease. To learn more aboutXenoPort, please visit the Web site atwww.XenoPort.com. HORIZANT, REGNITE andXENOPORTare registered trademarks ofXenoPort, Inc. XNPT2G Contact: XenoPort, Inc. Jackie Cossmon, 408-616-7220 ir@XenoPort.com
XenoPort Urges Stockholders to Vote "FOR ALL" XenoPort Director Nominees on the WHITE Proxy Card
Press spacebar to pause and continue. Press esc to stop.